 chemotherapi cisplatin cisplatin vinblastin advanc non-smal cell lung cancer random phase II studi cancer leukemia group forty-seven patient nonresect non-smal cell lung cancer nsclc prospect random phase II trial respons assess possibl patient patient evalu surviv thirteen partial respons regress evalu diseas patient cisplatin confid interv CI median time progress month median surviv time month plu twenty-thre partial respons regress evalu diseas patient vinblastin CI median time progress month median surviv time month dose equival treatment regimen sixteen patient perform statu patient perform statu patient perform statu patient locoregion radiat therapi overal respons rate prior radiat therapi group median surviv time patient perform statu month month patient perform statu perform statu signific factor time progress frequent sever leukopenia fever genitourinari GU toxic pulmonari toxic treatment-rel death treatment-rel death grade iii/vi myelotox prior radiat therapi perform statu regimen activ standard therapi advanc nsclc